NL-OMON47411已完成2 期
MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer - Vinorelbine in BRAF-like colon carcinoma
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Written informed consent (+ TR (translational research)) must be given according to ICH/GCP and national/local regulations
- •2. Written documentation of BRAF-like signature CC, including BRAFm and BRAFwt, as determined by the validated assay of Agendia
- •3. written documentation of KRAS and BRAF mutational status
- •4. Age * 18 years
- •5. Histologically proven and measurable (RECIST criteria v.1.1) metastatic adenocarcinoma of the colon not in a previously irradiated area, treated with one or two lines of standard of care therapy, including BRAF inhibitors, for locally advanced disease and metastatic disease
- •6. WHO performance status of 0-1
- •7.Life expectancy > 3 months allowing adequate follow up of toxicity evaluation and antitumor activity
- •8. Negative urine pregnancy test for female patients with childbearing potential
排除标准
- •1. Any treatment with investigational drugs, including BRAF inhibitors, within 28 days prior to receiving the first dose of investigational treatment
- •2. Symptomatic or untreated leptomeningeal disease;3. Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy (for at least 4 weeks) are allowed to enroll. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs or corticosteroids;4. Impairment of gastrointestinal (GI) function or GI disease (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, any condition inducing malabsorption, small bowel resection);5. Other uncontrolled concomitant illness, including serious uncontrolled intercurrent infection;6. Known allergy or any other adverse reaction to any of the drugs or to any related compound;7. Women who are pregnant or breast feeding;8. Unreliable contraceptive methods. Both men and women enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms);9. Patients who have undergone any major surgery within the last 2 weeks prior to starting study drug or who would not have fully recovered from previous surgery;10. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;11. Patients with a known history of hepatitis B or C;12. Known hypersensitivity to study drug or excipients
研究者
相似试验
已完成
3 期
A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension period in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatmentDiabetes mellitus type 210018424diabetesNL-OMON38357Boehringer Ingelheim18
已完成
2 期
A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation.NL-OMON49029Khondrion B.V.9
已完成
2 期
Phase II study of nilotinib efficacy in pigmented villo-nodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)Pigmented Villonodulair Synovitis (PVNS) Giant Cell Tumor of Tendon10013361NL-OMON36562eids Universitair Medisch Centrum16
已完成
2 期
A phase IIa, placebo-controlled, double blind, randomised multicentre pilot study to investigate the efficacy, safety and tolerability of the monoclonal antibody ATH3G10 in patients with ST-elevation myocardial infarctioNL-OMON48214Athera Biotechnologies AB16
已完成
不适用
An open-label, adaptive multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of RO7234292 in csf and plasma, and safety and tolerability following intrathecal administration in patients with Huntington's disease.Chronic Progressive Choreadegenerative chorea1002929910029317NL-OMON49037Hoffmann-La Roche4